Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.

Gunderson CC, Erickson BK, Wilkinson-Ryan I, Vesely SK, Leath CA 3rd, Gehrig PA, Moore KN.

Am J Clin Oncol. 2019 Feb;42(2):138-142. doi: 10.1097/COC.0000000000000498.

PMID:
30557164
2.

Quantitative accuracy of positron emission tomography/magnetic resonance and positron emission tomography/computed tomography for cervical cancer.

Oldan JD, Khandani AH, Fielding JR, Jones EL, Gehrig PA, Sills TM, Roy P, Lin W.

World J Nucl Med. 2018 Oct-Dec;17(4):213-218. doi: 10.4103/wjnm.WJNM_56_17.

3.

Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.

Tran AQ, Erim DO, Sullivan SA, Cole AL, Barber EL, Kim KH, Gehrig PA, Wheeler SB.

Gynecol Oncol. 2018 Feb;148(2):329-335. doi: 10.1016/j.ygyno.2017.12.015. Epub 2017 Dec 19.

4.

Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?

Barber EL, Rossi EC, Gehrig PA.

Gynecol Oncol. 2017 Dec;147(3):607-611. doi: 10.1016/j.ygyno.2017.09.016. Epub 2017 Sep 21.

5.

Sexual Health Before Treatment in Women with Suspected Gynecologic Malignancy.

Bretschneider CE, Doll KM, Bensen JT, Gehrig PA, Wu JM, Geller EJ.

J Womens Health (Larchmt). 2017 Dec;26(12):1326-1332. doi: 10.1089/jwh.2016.6307. Epub 2017 Aug 22.

6.

Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality?

Barber EL, Doll KM, Gehrig PA.

Gynecol Oncol. 2017 Aug;146(2):368-372. doi: 10.1016/j.ygyno.2017.05.012. Epub 2017 May 16.

7.

Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.

Baker WD, Pierce SR, Mills AM, Gehrig PA, Duska LR.

Gynecol Oncol. 2017 Jul;146(1):34-38. doi: 10.1016/j.ygyno.2017.04.006. Epub 2017 Apr 18.

PMID:
28427775
8.

Perioperative sexual interest in women with suspected gynecologic malignancies.

Bretschneider CE, Bensen JT, Geller EJ, Gehrig PA, Wu JM, Doll KM.

Gynecol Oncol. 2017 Jul;146(1):109-113. doi: 10.1016/j.ygyno.2017.04.001. Epub 2017 Apr 12.

PMID:
28410756
9.

Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.

Barber EL, Dusetzina SB, Stitzenberg KB, Rossi EC, Gehrig PA, Boggess JF, Garrett JM.

Gynecol Oncol. 2017 Jun;145(3):500-507. doi: 10.1016/j.ygyno.2017.03.014. Epub 2017 Mar 31.

10.

Robotic Radical Parametrectomy With Upper Vaginectomy and Pelvic Lymphadenectomy in Patients With Occult Cervical Carcinoma After Extrafascial Hysterectomy.

Tran AQ, Sullivan SA, Gehrig PA, Soper JT, Boggess JF, Kim KH.

J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):757-763. doi: 10.1016/j.jmig.2017.02.016. Epub 2017 Feb 22. Review.

PMID:
28254677
11.

Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.

Pierce SR, Stine JE, Gehrig PA, Havrilesky LJ, Secord AA, Nakayama J, Snavely AC, Moore DT, Kim KH.

Gynecol Oncol. 2017 Mar;144(3):531-535. doi: 10.1016/j.ygyno.2016.12.024. Epub 2017 Jan 3.

PMID:
28062116
12.

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.

Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ, Martin G, Soper SA.

NPJ Precis Oncol. 2017;1. pii: 24. doi: 10.1038/s41698-017-0028-8. Epub 2017 Jul 25.

13.

Sebaceous carcinoma of the vulva: A case report and review of the literature.

Sullivan SA, Tran AQ, O'Connor S, Gehrig PA.

Gynecol Oncol Rep. 2016 Oct 29;18:40-41. eCollection 2016 Nov.

14.

Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.

Yuan L, Sheng X, Clark LH, Zhang L, Guo H, Jones HM, Willson AK, Gehrig PA, Zhou C, Bae-Jump VL.

Am J Transl Res. 2016 Oct 15;8(10):4265-4277. eCollection 2016.

15.

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer.

Suri A, Sheng X, Schuler KM, Zhong Y, Han X, Jones HM, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Jun 28;7(26):39582-39594. doi: 10.18632/oncotarget.8659.

16.

Trainee Participation in Benign Hysterectomy: Effects of Surgical Approach and Operative Time.

Barber EL, Harris B, Gehrig PA.

J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S76. doi: 10.1016/j.jmig.2015.08.202. Epub 2015 Oct 15. No abstract available.

PMID:
27679334
17.

NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo.

Zhang L, Han J, Jackson AL, Clark LN, Kilgore J, Guo H, Livingston N, Batchelor K, Yin Y, Gilliam TP, Gehrig PA, Sheng X, Zhou C, Bae-Jump VL.

J Hematol Oncol. 2016 Sep 21;9(1):91.

18.

JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.

Qiu H, Li J, Clark LH, Jackson AL, Zhang L, Guo H, Kilgore JE, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Oct 11;7(41):66809-66821. doi: 10.18632/oncotarget.11631.

19.

Does the Robotic Platform Reduce Morbidity Associated With Combined Radical Surgery and Adjuvant Radiation for Early Cervical Cancers?

Clark LH, Barber EL, Gehrig PA, Soper JT, Boggess JF, Kim KH.

Int J Gynecol Cancer. 2016 Oct;26(8):1485-9. doi: 10.1097/IGC.0000000000000775.

20.

Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Kilgore J, Jackson AL, Clark LH, Guo H, Zhang L, Jones HM, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Am J Transl Res. 2016 Jun 15;8(6):2705-15. eCollection 2016.

21.

Intraoperative Handoffs and Postoperative Complications Among Patients Undergoing Gynecologic Oncology Operations.

Doll KM, Lavery JA, Snavely AC, Gehrig PA.

J Healthc Qual. 2017 Jul/Aug;39(4):e42-e48. doi: 10.1097/JHQ.0000000000000042.

22.

Who presents satisfied? Non-modifiable factors associated with patient satisfaction among gynecologic oncology clinic patients.

Barber EL, Bensen JT, Snavely AC, Gehrig PA, Doll KM.

Gynecol Oncol. 2016 Aug;142(2):299-303. doi: 10.1016/j.ygyno.2016.06.009. Epub 2016 Jun 11.

23.

Venous Thromboembolism in Minimally Invasive Compared With Open Hysterectomy for Endometrial Cancer.

Barber EL, Gehrig PA, Clarke-Pearson DL.

Obstet Gynecol. 2016 Jul;128(1):121-6. doi: 10.1097/AOG.0000000000001492.

24.

Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.

Barber EL, Rutstein SE, Miller WC, Gehrig PA.

Gynecol Oncol. 2016 Aug;142(2):380. doi: 10.1016/j.ygyno.2016.05.038. Epub 2016 Jun 3. No abstract available.

PMID:
27264077
25.

Clinical Benefits Associated With Medicaid Coverage Before Diagnosis of Gynecologic Cancers.

Doll KM, Basch EM, Meng K, Barber EL, Gehrig PA, Brewster WR, Meyer AM.

J Oncol Pract. 2016 Jun;12(6):e724-33. doi: 10.1200/JOP.2016.011080. Epub 2016 May 31.

26.

Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.

Wysham WZ, Roque DR, Han J, Zhang L, Guo H, Gehrig PA, Zhou C, Bae-Jump VL.

Target Oncol. 2016 Dec;11(6):763-769.

PMID:
27188391
27.

The impact of surgical complications on health-related quality of life in women undergoing gynecologic and gynecologic oncology procedures: a prospective longitudinal cohort study.

Doll KM, Barber EL, Bensen JT, Revilla MC, Snavely AC, Bennett AV, Reeve BB, Gehrig PA.

Am J Obstet Gynecol. 2016 Oct;215(4):457.e1-457.e13. doi: 10.1016/j.ajog.2016.04.025. Epub 2016 Apr 27.

28.

Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women.

Doll KM, Meng K, Gehrig PA, Brewster WR, Meyer AM.

Am J Obstet Gynecol. 2016 Oct;215(4):447.e1-447.e13. doi: 10.1016/j.ajog.2016.04.020. Epub 2016 Apr 26.

29.

Extremes in body mass index affect overall survival in women with cervical cancer.

Clark LH, Jackson AL, Soo AE, Orrey DC, Gehrig PA, Kim KH.

Gynecol Oncol. 2016 Jun;141(3):497-500. doi: 10.1016/j.ygyno.2016.03.035. Epub 2016 Apr 15.

PMID:
27058838
30.

Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.

Guo H, Zhong Y, Jackson AL, Clark LH, Kilgore J, Zhang L, Han J, Sheng X, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Apr 12;7(15):20338-56. doi: 10.18632/oncotarget.7934.

31.

The health-related quality of life journey of gynecologic oncology surgical patients: Implications for the incorporation of patient-reported outcomes into surgical quality metrics.

Doll KM, Barber EL, Bensen JT, Snavely AC, Gehrig PA.

Gynecol Oncol. 2016 May;141(2):329-335. doi: 10.1016/j.ygyno.2016.03.003. Epub 2016 Mar 18.

32.

Cervical Cancer in Women Aged 35 Years and Younger.

Pelkofski E, Stine J, Wages NA, Gehrig PA, Kim KH, Cantrell LA.

Clin Ther. 2016 Mar;38(3):459-66. doi: 10.1016/j.clinthera.2016.01.024. Epub 2016 Feb 18.

PMID:
26899314
33.

Trainee participation and perioperative complications in benign hysterectomy: the effect of route of surgery.

Barber EL, Harris B, Gehrig PA.

Am J Obstet Gynecol. 2016 Aug;215(2):215.e1-7. doi: 10.1016/j.ajog.2016.02.022. Epub 2016 Feb 13.

PMID:
26884272
34.

Prevalence of pelvic floor disorders in women with suspected gynecological malignancy: a survey-based study.

Bretschneider CE, Doll KM, Bensen JT, Gehrig PA, Wu JM, Geller EJ.

Int Urogynecol J. 2016 Sep;27(9):1409-14. doi: 10.1007/s00192-016-2962-3. Epub 2016 Feb 12.

35.

Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.

Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, Gehrig PA, Zamboni WC.

Cancer Chemother Pharmacol. 2016 Mar;77(3):565-73. doi: 10.1007/s00280-015-2945-y. Epub 2016 Jan 28.

PMID:
26822231
36.

Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.

Roque DR, Taylor KN, Palisoul M, Wysham WZ, Milam B, Robison K, Gehrig PA, Raker C, Kim KH.

Int J Gynecol Cancer. 2016 Mar;26(3):505-11. doi: 10.1097/IGC.0000000000000634.

PMID:
26807641
37.

Adjuvant Treatment and Clinical Trials in Elderly Patients With Endometrial Cancer: A Time for Change?

Clark LH, Jackson AL, Gehrig PA, Bae-Jump V, Van Le L, Ko EM.

Int J Gynecol Cancer. 2016 Feb;26(2):282-9. doi: 10.1097/IGC.0000000000000605.

PMID:
26745698
38.

Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.

Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ 3rd.

Gynecol Oncol. 2016 Feb;140(2):234-8. doi: 10.1016/j.ygyno.2015.12.010. Epub 2015 Dec 17.

PMID:
26706662
39.

Endometrial Cancer Survivors' Perceptions of Provider Obesity Counseling and Attempted Behavior Change: Are We Seizing the Moment?

Clark LH, Ko EM, Kernodle A, Harris A, Moore DT, Gehrig PA, Bae-Jump V.

Int J Gynecol Cancer. 2016 Feb;26(2):318-24. doi: 10.1097/IGC.0000000000000596.

PMID:
26588234
40.

Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer.

Barber EL, Boggess JF, Van Le L, Kim KH, Bae-Jump VL, Brewster WR, Soper JT, Gehrig PA.

Obstet Gynecol. 2015 Dec;126(6):1191-7. doi: 10.1097/AOG.0000000000001138.

PMID:
26551182
41.

Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.

Secord AA, Hasselblad V, Von Gruenigen VE, Gehrig PA, Modesitt SC, Bae-Jump V, Havrilesky LJ.

Gynecol Oncol. 2016 Jan;140(1):184-90. doi: 10.1016/j.ygyno.2015.10.020. Epub 2015 Oct 31. Review.

PMID:
26524722
42.

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.

Stine JE, Guo H, Sheng X, Han X, Schointuch MN, Gilliam TP, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2016 Jan 5;7(1):946-60. doi: 10.18632/oncotarget.5834.

43.

A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery.

Barber EL, Rutstein S, Miller WC, Gehrig PA.

Gynecol Oncol. 2015 Dec;139(3):401-6. doi: 10.1016/j.ygyno.2015.09.080. Epub 2015 Oct 23.

44.

Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer.

Zhang C, Roque D, Ehrisman JA, DiSanto N, Broadwater G, Doll KM, Gehrig PA, Secord AA, Havrilesky LJ.

Gynecol Oncol Rep. 2015 Jun 18;13:49-52. doi: 10.1016/j.gore.2015.06.004. eCollection 2015 Aug.

45.

A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.

Dickson EL, Vogel RI, Gehrig PA, Pierce S, Havrilesky L, Secord AA, Dottino J, Fader AN, Ricci S, Geller MA.

Gynecol Oncol. 2015 Nov;139(2):275-82. doi: 10.1016/j.ygyno.2015.09.002. Epub 2015 Sep 6.

46.

Gynecologic cancer outcomes in the elderly poor: A population-based study.

Doll KM, Meng K, Basch EM, Gehrig PA, Brewster WR, Meyer AM.

Cancer. 2015 Oct 15;121(20):3591-9. doi: 10.1002/cncr.29541. Epub 2015 Jul 31.

47.

Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.

Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoshchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC.

Nanomedicine. 2015 Oct;11(7):1797-807. doi: 10.1016/j.nano.2015.05.007. Epub 2015 Jun 17.

PMID:
26093057
48.

JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer.

Qiu H, Jackson AL, Kilgore JE, Zhong Y, Chan LL, Gehrig PA, Zhou C, Bae-Jump VL.

Oncotarget. 2015 Mar 30;6(9):6915-30.

49.

Obesity and perioperative pulmonary complications in robotic gynecologic surgery.

Wysham WZ, Kim KH, Roberts JM, Sullivan SA, Campbell SB, Roque DR, Moore DT, Gehrig PA, Boggess JF, Soper JT, Huh WK.

Am J Obstet Gynecol. 2015 Jul;213(1):33.e1-33.e7. doi: 10.1016/j.ajog.2015.01.033. Epub 2015 Jan 28.

PMID:
25637843
50.

Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cells.

Nair SV, Witek MA, Jackson JM, Lindell MA, Hunsucker SA, Sapp T, Perry CE, Hupert ML, Bae-Jump V, Gehrig PA, Wysham WZ, Armistead PM, Voorhees P, Soper SA.

Chem Commun (Camb). 2015 Feb 21;51(15):3266-9. doi: 10.1039/c4cc09765c.

Supplemental Content

Loading ...
Support Center